Testing cevostamab for lupus with kidney involvement
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug called cevostamab for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body's own tissues. Some participants also have lupus nephritis, which means the disease is affecting their kidneys. The drug may help by targeting a specific part of the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed SLE diagnosis for at least 6 months before the study starts
- If you have lupus kidney disease, it must be confirmed by a kidney biopsy within 9 months of screening
- Active lupus disease confirmed by blood tests (SLEDAI-2K score)
- Previous lupus treatments haven't worked well enough or caused side effects you couldn't tolerate
- Not pregnant, breastfeeding, or planning to become pregnant during the study
- No recent or current serious infections, TB, or certain other immune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an investigational drug called cenerimod can safely and effectively treat active lupus nephritis when added to your regular lupus medications. It's for people with recent kidney biopsy showing active lupus kidney disease and high protein in urine.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
This study compares two medications, Telitacicept and Belimumab, to see which works better for people with active lupus that hasn't improved with standard treatments. The goal is to find a more effective option for managing symptoms.
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.